As of Oct 26, 2026: 150 trial data dates in the next 90 days. Scores as of 7:29 PM ET, 15 minutes behind.
Biotech trial data dates
Phase 2 and 3 trials, next 90 days
The day a trial's main results are due, as the sponsor lists it on ClinicalTrials.gov.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Pro members see it live.
See all 150 trial dates, rankedSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.
Sign inSigned out. Sign in to keep going.
No password. Nothing else to fill in.
Your guest pass has ended. No password needed.
Upgrade to ProEvery stock ranked, with prices that refresh every 2.5 seconds during market hours.
Trial data dates by month
The sponsors' estimates. Results often come weeks or months later.
| Date | Stock | Drug | Cash runway | Quality Score |
|---|---|---|---|---|
| October 202628 | ||||
| October 202628 | ||||
| October 202628 | ||||
| Oct26Mon | Inclisiran sodiumPhase 3, estimated · today | Not countedBalance Dec 2025 | 11 | |
| Oct28Wed | BelzutifanPhase 3, estimated · in 2 days | Brings in cashBalance Jun 30 | 7 | |
| Oct29Thu | IanalumabPhase 3, estimated · in 3 days | Not countedBalance Dec 2025 | 11 | |
| Oct30Fri | EncorafenibPhase 3, estimated · in 4 days | Brings in cashBalance Jun 28 | 15 | |
| Oct30Fri | Vanzacaftor triplePhase 3, estimated · in 4 days | Brings in cashBalance Jun 30 | 14 | |
| 2026Oct | SabirnetugPhase 2, estimated · this month | About 4 quartersBalance Jun 30 | -4 | |
| Oct31Sat | ADG126Phase 1/2, estimated · in 5 days | Not countedBalance Dec 2025 | -3 | |
| Oct31Sat | CapivasertibPhase 3, estimated · in 5 days | Not countedBalance Dec 2025 | 9 | |
| 2026Oct | BHV-7000Phase 2/3, estimated · this month | About 2 quartersBalance Jun 30 | 2 | |
| 2026Oct | BarzolvolimabPhase 3, estimated · this month | About 12 quartersBalance Jun 30 | -3 | |
| 2026Oct | DazucorilantPhase 2, estimated · this month | Brings in cashBalance Jun 30 | 9 | |
| 2026Oct | N-803Phase 2, estimated · this month | About 5 quartersBalance Jun 30 | 4 | |
| 2026Oct | BrenetafuspPhase 1/2, estimated · this month | Not countedBalance Jun 30 | 0 | |
| 2026Oct | IMVT-1402Phase 2, estimated · this month | About 7 quartersBalance Jun 30 | -6 | |
| 2026Oct | DISC-0974Phase 2, estimated · this month | About 14 quartersBalance Jun 30 | 3 | |
| 2026Oct | BaricitinibPhase 3, estimated · this month | Brings in cashBalance Jun 30 | 18 | |
| 2026Oct | RetatrutidePhase 3, estimated · this month | Brings in cashBalance Jun 30 | 18 | |
| 2026Oct | MaralixibatPhase 3, estimated · this month | Not countedBalance Jun 30 | 0 | |
| 2026Oct | Tapinarof creamPhase 3, estimated · this month | Brings in cashBalance Jun 30 | 0 | |
| Oct31Sat | PalazestrantPhase 3, estimated · in 5 days | About 11 quartersBalance Jun 30 | -6 | |
| Oct31Sat | SetmelanotidePhase 2, estimated · in 5 days | About 12 quartersBalance Jun 30 | 2 | |
| Oct31Sat | EteplirsenPhase 3, estimated · in 5 days | Brings in cashBalance Jun 30 | -3 | |
| Oct31Sat | SPY002-072Phase 2, estimated · in 5 days | Into the second…The company's words | 6 | |
| Oct31Sat | TEV-56248Phase 3, estimated · in 5 days | Brings in cashBalance Jun 30 | 17 | |
| Oct31Sat | UblituximabPhase 3, estimated · in 5 days | Brings in cashBalance Jun 30 | 13 | |
| 2026Oct | IloperidonePhase 2, estimated · this month | About 4 quartersBalance Jun 30 | -9 | |
| 2026Oct | WVE-N531Phase 1/2, estimated · this month | About 7 quartersBalance Jun 30 | -7 | |
| 2026Oct | AzetukalnerPhase 3, estimated · this month | About 14 quartersBalance Jun 30 | -2 | |
| November 202635 | ||||
| November 202635 | ||||
| November 202635 | ||||
| Nov1Sun | KarXTPhase 3, estimated · in 6 days | Brings in cashBalance Jun 30 | 10 | |
| Nov1Sun | CRB-601Phase 1/2, estimated · in 6 days | About 5 quartersBalance Jun 30 | -10 | |
| Nov1Sun | ApitegromabPhase 3, estimated · in 6 days | About 6 quartersBalance Jun 30 | -2 | |
| Nov2Mon | AnifrolumabPhase 3, estimated · in 7 days | Not countedBalance Dec 2025 | 9 | |
| Nov2Mon | KarXTPhase 3, estimated · in 7 days | Brings in cashBalance Jun 30 | 10 | |
| Nov3Tue | LOU064Phase 3, estimated · in 8 days | Not countedBalance Dec 2025 | 11 | |
| Nov5Thu | ParsaclisibPhase 2, estimated · in 10 days | Brings in cashBalance Mar 31 | 9 | |
| Nov11Wed | PRGN-2009Phase 2, estimated · in 16 days | About 1 quarterBalance Jun 30 | 4 | |
| Nov15Sun | CytisiniclinePhase 3, estimated · in 20 days | About 15 quartersBalance Jun 30 | 2 | |
| Nov18Wed | DeucravacitinibPhase 3, estimated · in 23 days | Brings in cashBalance Jun 30 | 10 | |
| Nov20Fri | PovorcitinibPhase 2, estimated · in 25 days | Brings in cashBalance Mar 31 | 9 | |
| Nov20Fri | PembrolizumabPhase 3, estimated · in 25 days | Brings in cashBalance Jun 30 | 7 | |
| Nov24Tue | KarXTPhase 3, estimated · in 29 days | Brings in cashBalance Jun 30 | 10 | |
| Nov29Sun | RimegepantPhase 3, estimated · in 34 days | Brings in cashBalance Jun 28 | 15 | |
| 2026Nov | ALKS 2680Phase 2, estimated · next month | Brings in cashBalance Jun 30 | 12 | |
| Nov30Mon | ARV-806Phase 1/2, estimated · in 35 days | About 11 quartersBalance Jun 30 | -1 | |
| Nov30Mon | AU-011Phase 2, estimated · in 35 days | Into 1H 2029The company's words | -4 | |
| Nov30Mon | BGE-102Phase 2, estimated · in 35 days | Through 2029The company's words | -7 | |
| 2026Nov | Drug not namedPhase 2, estimated · next month | Not countedBalance Dec 2025 | -3 | |
| 2026Nov | Cretostimogene…Phase 3, estimated · next month | Through 2029The company's words | 4 | |
| 2026Nov | OnvansertibPhase 2, estimated · next month | About 3 quartersBalance Jun 30 | -5 | |
| 2026Nov | DBV712Phase 3, estimated · next month | About 4 quartersBalance Jun 30 | -2 | |
| 2026Nov | N-803 and BCGPhase 2, estimated · next month | About 5 quartersBalance Jun 30 | 4 | |
| Nov30Mon | Drug not namedPhase 1/2, estimated · in 35 days | Not countedBalance Jun 30 | 0 | |
| 2026Nov | IMU-838Phase 3, estimated · next month | About 7 quartersBalance Jun 30 | -9 | |
| 2026Nov | TirzepatidePhase 3, estimated · next month | Brings in cashBalance Jun 30 | 18 | |
| 2026Nov | RetatrutidePhase 3, estimated · next month | Brings in cashBalance Jun 30 | 18 | |
| 2026Nov | ObicetrapibPhase 3, estimated · next month | About 18 quartersBalance Jun 30 | -5 | |
| 2026Nov | Drug not namedPhase 2, estimated · next month | About 18 quartersBalance Jun 30 | -5 | |
| 2026Nov | PCRX-201Phase 2, estimated · next month | Brings in cashBalance Jun 30 | 17 | |
| Nov30Mon | AMT-260Phase 1/2, estimated · in 35 days | Into 2030The company's words | -2 | |
| Nov30Mon | Drug not namedPhase 1/2, estimated · in 35 days | About 8 quartersBalance Jun 30 | -7 | |
| Nov30Mon | RilzabrutinibPhase 3, estimated · in 35 days | Not countedBalance Dec 2025 | 5 | |
| 2026Nov | TYRA-300Phase 1/2, estimated · next month | Into 2H 2028The company's words | -3 | |
| 2026Nov | TobevibartPhase 2, estimated · next month | Not countedBalance Jun 30 | 7 | |
| December 202659 | ||||
| December 202659 | ||||
| December 202659 | ||||
| Dec1Tue | FelzartamabPhase 3, estimated · in 36 days | Brings in cashBalance Mar 31 | 14 | |
| Dec1Tue | ApalutamidePhase 3, estimated · in 36 days | Brings in cashBalance Jun 28 | 12 | |
| Dec1Tue | TradipitantPhase 3, estimated · in 36 days | About 4 quartersBalance Jun 30 | -9 | |
| Dec1Tue | AzenosertibPhase 2, estimated · in 36 days | About 5 quartersBalance Jun 30 | -8 | |
| Dec2Wed | PF-06821497Phase 3, estimated · in 37 days | Brings in cashBalance Jun 28 | 15 | |
| Dec8Tue | MilvexianPhase 3, estimated · in 43 days | Brings in cashBalance Jun 28 | 12 | |
| Dec9Wed | KarXTPhase 3, estimated · in 44 days | Brings in cashBalance Jun 30 | 10 | |
| Dec15Tue | XL092Phase 3, estimated · in 50 days | Brings in cashBalance Jul 3 | 17 | |
| Dec15Tue | RezatapoptPhase 1/2, estimated · in 50 days | About 4 quartersBalance Jun 30 | -5 | |
| Dec26Sat | PovorcitinibPhase 3, estimated · in 61 days | Brings in cashBalance Mar 31 | 9 | |
| Dec28Mon | PF-06821497Phase 3, estimated · in 63 days | Brings in cashBalance Jun 28 | 15 | |
| Dec30Wed | CetrelimabPhase 3, estimated · in 65 days | Brings in cashBalance Jun 28 | 12 | |
| Dec30Wed | SeltorexantPhase 3, estimated · in 65 days | Brings in cashBalance Jun 28 | 12 | |
| Dec30Wed | EverolimusPhase 3, estimated · in 65 days | Not countedBalance Dec 2025 | 11 | |
| Dec30Wed | VepdegestrantPhase 3, estimated · in 65 days | Brings in cashBalance Jun 28 | 15 | |
| Dec30Wed | SLS009Phase 1/2, estimated · in 65 days | About 19 quartersBalance Jun 30 | 3 | |
| Dec30Wed | BIS-001Phase 1/2, estimated · in 65 days | Brings in cashBalance Jun 30 | -1 | |
| 2026Dec | ObefazimodPhase 2, estimated · in 2 months | Into Q4 2029The company's words | -2 | |
| 2026Dec | ALTO-300Phase 2, estimated · in 2 months | Through 2030The company's words | -1 | |
| 2026Dec | Bemnifosbuvir-ruzasvirPhase 3, estimated · in 2 months | About 5 quartersBalance Jun 30 | 1 | |
| 2026Dec | AP02Phase 2, estimated · in 2 months | Not countedBalance Jun 30 | 1 | |
| 2026Dec | SolriamfetolPhase 3, estimated · in 2 months | Not countedBalance Jun 30 | 2 | |
| Dec31Thu | DurvalumabPhase 3, estimated · in 66 days | Not countedBalance Dec 2025 | 9 | |
| Dec31Thu | BT5528Phase 1/2, estimated · in 66 days | Into 2030The company's words | -5 | |
| 2026Dec | BEAM-201Phase 1/2, estimated · in 2 months | About 12 quartersBalance Jun 30 | 3 | |
| 2026Dec | BHV-7000Phase 2/3, estimated · in 2 months | About 2 quartersBalance Jun 30 | 2 | |
| 2026Dec | RelacorilantPhase 2, estimated · in 2 months | Brings in cashBalance Jun 30 | 9 | |
| 2026Dec | DNL593Phase 1/2, estimated · in 2 months | About 8 quartersBalance Jun 30 | 0 | |
| 2026Dec | ClaseprubartPhase 2, estimated · in 2 months | Into 2030The company's words | -2 | |
| 2026Dec | DT-216P2Phase 1/2, estimated · in 2 months | Into 2029The company's words | -3 | |
| 2026Dec | EIK1001Phase 2, estimated · in 2 months | Not countedBalance Jun 30 | 0 | |
| 2026Dec | Drug not namedPhase 1/2, estimated · in 2 months | Not countedBalance Dec 2025 | -1 | |
| 2026Dec | Sacituzumab GovitecanPhase 3, estimated · in 2 months | Brings in cashBalance Jun 30 | 13 | |
| 2026Dec | Olvimulogene…Phase 3, estimated · in 2 months | About 3 quartersBalance Jun 30 | -12 | |
| 2026Dec | Drug not namedPhase 3, estimated · in 2 months | Brings in cashBalance Jun 30 | -1 | |
| Dec31Thu | Treprostinil PalmitilPhase 2/3, estimated · in 66 days | About 6 quartersBalance Jun 30 | 1 | |
| 2026Dec | DonidalorsenPhase 3, estimated · in 2 months | Not countedBalance Jun 30 | -4 | |
| Dec31Thu | ZanidatamabPhase 2, estimated · in 66 days | Brings in cashBalance Jun 30 | 6 | |
| Dec31Thu | IbrutinibPhase 3, estimated · in 66 days | Brings in cashBalance Jun 28 | 12 | |
| 2026Dec | TonlamarsenPhase 2, estimated · in 2 months | Not countedBalance Jun 30 | -1 | |
| 2026Dec | KB803Phase 3, estimated · in 2 months | Brings in cashBalance Jun 30 | 9 | |
| 2026Dec | KB801Phase 1/2, estimated · in 2 months | Brings in cashBalance Jun 30 | 9 | |
| 2026Dec | Drug not namedPhase 1/2, estimated · in 2 months | About 10 quartersBalance Jun 30 | -12 | |
| 2026Dec | VDPHL01Phase 3, estimated · in 2 months | Not countedBalance Jun 30 | 9 | |
| 2026Dec | ResmetiromPhase 3, estimated · in 2 months | Not countedBalance Jun 30 | 2 | |
| 2026Dec | LicaminlimabPhase 2/3, estimated · in 2 months | Not countedBalance Dec 2025 | -3 | |
| 2026Dec | OMS906 study drugPhase 2, estimated · in 2 months | Not countedBalance Jun 30 | 6 | |
| Dec31Thu | ZanubrutinibPhase 3, estimated · in 66 days | Brings in cashBalance Jun 30 | 17 | |
| 2026Dec | ZILRETTAPhase 3, estimated · in 2 months | Brings in cashBalance Jun 30 | 17 | |
| Dec31Thu | PF04518600Phase 3, estimated · in 66 days | Brings in cashBalance Jun 28 | 15 | |
| 2026Dec | Drug not namedPhase 3, estimated · in 2 months | Into 2028The company's words | -3 | |
| 2026Dec | Drug not namedPhase 3, estimated · in 2 months | Into 2028The company's words | -3 | |
| Dec31Thu | SRP-1003Phase 1/2, estimated · in 66 days | Brings in cashBalance Jun 30 | -3 | |
| Dec31Thu | Drug not namedPhase 2, estimated · in 66 days | Brings in cashBalance Jun 30 | -1 | |
| 2026Dec | TARA-002Phase 2, estimated · in 2 months | About 8 quartersBalance Jun 30 | -7 | |
| Dec31Thu | Drug not namedPhase 2, estimated · in 66 days | Brings in cashBalance Jun 30 | 7 | |
| 2026Dec | TobevibartPhase 3, estimated · in 2 months | Not countedBalance Jun 30 | 7 | |
| Dec31Thu | TobevibartPhase 3, estimated · in 66 days | Not countedBalance Jun 30 | 7 | |
| 2026Dec | VQW-765Phase 3, estimated · in 2 months | About 4 quartersBalance Jun 30 | -9 | |
| January 202728 | ||||
| January 202728 | ||||
| January 202728 | ||||
| Jan12027 | TecovirimatPhase 2, estimated · in 67 days | Not countedBalance Jun 30 | -5 | |
| Jan42027 | AZD0780Phase 3, estimated · in 70 days | Not countedBalance Dec 2025 | 9 | |
| Jan42027 | SonelokimabPhase 3, estimated · in 70 days | Into the second…The company's words | -4 | |
| Jan62027 | AnifrolumabPhase 3, estimated · in 72 days | Not countedBalance Dec 2025 | 9 | |
| Jan62027 | Drug not namedPhase 1/2, estimated · in 72 days | Brings in cashBalance Mar 31 | 9 | |
| Jan82027 | OTX-TKIPhase 3, estimated · in 74 days | About 10 quartersBalance Jun 30 | -7 | |
| Jan112027 | AZD0780Phase 3, estimated · in 77 days | Not countedBalance Dec 2025 | 9 | |
| Jan112027 | OsimertinibPhase 3, estimated · in 77 days | Not countedBalance Dec 2025 | 9 | |
| Jan122027 | PembrolizumabPhase 3, estimated · in 78 days | Brings in cashBalance Jun 30 | 7 | |
| Jan132027 | TezepelumabPhase 3, estimated · in 79 days | Not countedBalance Dec 2025 | 9 | |
| Jan152027 | IDE196Phase 2/3, estimated · in 81 days | Not countedBalance Jun 30 | 2 | |
| Jan162027 | CRB-701Phase 1/2, estimated · in 82 days | About 5 quartersBalance Jun 30 | -10 | |
| Jan182027 | MaribavirPhase 3, estimated · in 84 days | No balance sheet | 13 | |
| Jan212027 | Maridebart Cafragluti…Phase 3, estimated · in 87 days | Brings in cashBalance Jun 30 | 19 | |
| Jan212027 | UblituximabPhase 3, estimated · in 87 days | Brings in cashBalance Jun 30 | 13 | |
| 2027Jan | LivmoniplimabPhase 2/3, estimated · in 3 months | Brings in cashBalance Jun 30 | 20 | |
| 2027Jan | Infigratinib /dayPhase 2/3, estimated · in 3 months | About 6 quartersBalance Jun 30 | 4 | |
| 2027Jan | BT8009Phase 1/2, estimated · in 3 months | Into 2030The company's words | -5 | |
| 2027Jan | AT-1501Phase 1/2, estimated · in 3 months | About 4 quartersBalance Jun 30 | -8 | |
| 2027Jan | SevasemtenPhase 2, estimated · in 3 months | About 1 quarterBalance Jun 30 | 5 | |
| 2027Jan | CTI-1601Phase 2, estimated · in 3 months | Not countedBalance Jun 30 | -9 | |
| 2027Jan | SotagliflozinPhase 3, estimated · in 3 months | About 11 quartersBalance Jun 30 | -6 | |
| 2027Jan | VolixibatPhase 2, estimated · in 3 months | Not countedBalance Jun 30 | 0 | |
| 2027Jan | Drug not namedPhase 3, estimated · in 3 months | Into 2028The company's words | -3 | |
| 2027Jan | SetrusumabPhase 3, estimated · in 3 months | About 3 quartersBalance Jun 30 | -2 | |
| 2027Jan | DomvanalimabPhase 2, estimated · in 3 months | About 6 quartersBalance Jun 30 | -10 | |
| 2027Jan | 68Ga-PSMA-11Phase 3, estimated · in 3 months | Not countedBalance Dec 2025 | 5 | |
| 2027Jan | AzetukalnerPhase 3, estimated · in 3 months | About 14 quartersBalance Jun 30 | -2 | |
Tested. Our top-scored stocks returned 2.2x the average stock over the next month. How we tested it ›
The FDA calendar: 19 FDA dates ahead ›
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Pro members see it live.
See all 150 trial dates, rankedSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.
Sign inSigned out. Sign in to keep going.
No password. Nothing else to fill in.
Your guest pass has ended. No password needed.
Upgrade to ProEvery stock ranked, with prices that refresh every 2.5 seconds during market hours.
Use this page
Kept by Andrew Gomes, Breakaway's founder, from the sponsors' listings on ClinicalTrials.gov. Updated Oct 26, 2026.
Free to reuse with a link to this page.
How to cite
Breakaway, Biotech trial data dates, next 90 days, Oct 26, 2026, getbreakaway.com/biotech/trial-dates
Journalists: email [email protected] for the data behind this page.
The PDUFA dates and FDA panels are on the FDA calendar.